Biocon and Mylan launch Trastuzumab biosimilar Ogivri in USA Ogivri was the first biosimilar of Herceptin to be approved by USFDA two years ago, for the treatment of HER2-overexpressing breast cancer and metastatic stomach cancer.
Feedback
BIOCON 
Reputation: 2,149 • Dec 3, 2019 1:04 AM
Vote
Comment
Share